摘要
近年来,南京市将生物医药产业作为城市主导产业,打造具有全球影响力的产业地标。2018年以来,南京生物医药产业的龙头企业陆续上市,在南京生物医药产业的“高地”的基础上,又增添了多座“高峰”,对产业发展起到了推动作用。与此同时,与同样将生物医药作为重点产业的苏州相较,企业上市数量上仍存在一定差距。论文通过两地上市企业数量、资产、市值等方向的对比研究,提出南京市在创新生态、核心企业市场表现出企业前瞻性上的不足,并以此提出完善培育体系、引导企业提升硬实力、优化创新生态、促进产业集聚发展的对策与建议。
In recent years,Nanjing has taken biomedical industry as the city's leading industry and built an industrial landmark with global influence.Since 2018,leading enterprises in Nanjing's biomedical industry have been listed one after another.On the basis of the"highland"of Nanjing's biomedical industry,several"peaks"have been added,which has played a driving role in promoting the development of the industry.At the same time,compared with Suzhou,which also takes biomedicine as a key industry,there is still a certain gap in the number of listed enterprises.Based on the comparative study of the number,assets and market value of listed companies in Nanjing and Suzhou,this paper puts forward the shortcomings of innovation ecology and core enterprise market,and puts forward countermeasures and suggestions,such as improving the cultivation system,guiding enterprises to enhance hard power,optimizing innovation ecology and promoting industrial agglomeration development.
作者
徐广磊
高春南
吴建峰
XU Guang-lei;GAO Chun-nan;WU Jian-feng(Nanjing Institute of Science and Technology Information,Nanjing 210018,China)
出处
《中小企业管理与科技》
2022年第7期52-55,共4页
Management & Technology of SME
基金
南京市软科学项目“提升南京制造业产业链现代化水平的研究”(项目编号:202101005)。
关键词
生物医药
上市企业
高质量发展
biological medicine
listed enterprises
high quality development
